This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Bristol-Myers Squibb
Bristol-Myers Squibb Company, commonly referred to as BMS, is a leading global biopharmaceutical firm headquartered in the United States. Founded in 1887, the company has established a strong presence in major operational regions, including North America, Europe, and Asia, focusing on innovative medicines in oncology, immunology, and cardiovascular disease. BMS is renowned for its groundbreaking therapies, such as Opdivo and Eliquis, which have transformed treatment paradigms and improved patient outcomes. The company’s commitment to research and development has positioned it as a key player in the pharmaceutical industry, consistently achieving significant milestones, including numerous FDA approvals and recognitions for its contributions to healthcare. With a robust pipeline and a dedication to addressing unmet medical needs, Bristol-Myers Squibb continues to solidify its market position as a pioneer in biopharmaceutical innovation.
DitchCarbon Score
How does Bristol-Myers Squibb's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bristol-Myers Squibb's score of 71 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Bristol-Myers Squibb's reported carbon emissions
In 2023, Bristol-Myers Squibb (BMS) reported significant carbon emissions across various regions, with total emissions amounting to approximately 2,117,929,000 kg CO2e globally. This includes 208,535,000 kg CO2e from Scope 1 (direct emissions) and 158,447,000 kg CO2e from Scope 2 (indirect emissions). Notably, the company has not disclosed Scope 3 emissions for this year, which typically encompass emissions from the entire value chain. BMS has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across all scopes by 2050. In the near term, the company targets a 54.6% reduction in absolute Scope 1 and 2 emissions by 2033, using 2022 as the baseline year. Additionally, BMS plans to reduce Scope 3 emissions from fuel and energy-related activities by the same percentage within the same timeframe. By 2040, BMS aims to achieve net neutrality in both Scope 1 and Scope 2 emissions. The company is also committed to ensuring that 75% of its suppliers, based on emissions from purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by 2028. Furthermore, BMS has pledged to reduce absolute Scope 1 and 2 emissions by 90% by 2050, alongside a similar reduction target for Scope 3 emissions. BMS's climate initiatives are aligned with the Science Based Targets initiative (SBTi), reinforcing its commitment to sustainable practices within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 210,540,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 150,790,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 69,630,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 00,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Bristol-Myers Squibb is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
